NFS-02

N/A

Report date: 2025/04/21 20:01:10

Base Information

Drug NameNFS-02
Drug Alias NamerAAV-ND1NFS-02NFS02
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionNADH-ubiquinone oxidoreductase chain 1 gene transference
TargetsNADH-ubiquinone oxidoreductase chain 1
Therapy Area/IndicationsOptic Atrophy, Hereditary, Leber
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesWuhan Neurophth Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuhan Neurophth Biotechnology Co Ltd
Inactive CompaniesNeurophth Therapeutics IncNewforth (Suzhou) Biotechnology Co Ltd
Active IndicationsOptic Atrophy, Hereditary, Leber
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A